Vivitrol, Mysimba (naltrexone) is a small molecule pharmaceutical. Naltrexone was first approved as Vivitrol on 2006-04-13. It is used to treat alcoholism, drug overdose, and opioid-related disorders in the USA. It has been approved in Europe to treat obesity and overweight. The pharmaceutical is active against mu-type opioid receptor, delta-type opioid receptor, and kappa-type opioid receptor. In addition, it is known to target delta-type opioid receptor and kappa-type opioid receptor. Naltrexone hydrochloride's patent is valid until 2029-10-15 (FDA).
|Indication||alcoholism, drug overdose, obesity, opioid-related disorders, overweight|
|Drug Class||Narcotic agonists/antagonists (normorphine type)|